Scalper1 News
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation’s earnings totaled 96 cents a share, reversing a year-earlier loss and beating analysts’ consensus by 13 cents, according to Thomson Reuters. Revenue soared 234% to $200.5 million, topping consensus by nearly $19 million. The company didn’t formally change guidance, but said Scalper1 News
Scalper1 News